Linda Powerless goes away, and the company immediately goes from paying a know-nothing simpleton 1 million dollars a year (so that she can use company equity to pay consultants 12 million dollars a year to do her job for her), to hiring someone for the same price (or less?) who is actually familiar with the biotech and regulatory space and can do the job they were hired to do without paying consultants 1 million dollars a month?
Yes and No. The problem isn’t LP alone. The product also is not exciting for big pharma. Otherwise, you’d have seen big pharma lining up before their competitors do. Roswell Park’s similar product was sold pennies on dollar and no big pharma showed interest.
You will find out the hard way when LP continues to dilute in pennies throughout 2026 and 2027 until they run out of shares again! ;)
Market Data 
Markets 
AI
